PHC Group has acquired Fa-Tech Diagnostics, a developer, producer and supplier of printing solutions for the labeling of tissues in diagnostic and research laboratories.
Because of the acquisition of Fa-Tech by PHC Group, Epredia, a subsidiary of PHC Group, can enter into a strategic partnership with Fa-Tech and thereby strengthen its position in the area of labeling and tracking of tissues for cancer diagnostics. Fa-Tech has developed a completely automated system that reduces the chances of mistakes and that can add more information to the label.
Lindenaar & Co acted as advisor to Fa-Tech and coordinated the entire transaction process, including the preparation of the information memorandum and financial model, structuring the transaction, coordinating the due diligence process and conducting the final negotiations regarding the transaction documentation.
Profile Fa-Tech Diagnostics
Fa-Tech Diagnostics is a Dutch-Italian company specialized in the development of printing solutions on cassettes for diagnostic and research laboratories. With a large network of distributors, Fa-Tech supplies to laboratories around the world.
Profile PHC Group
PHC Group is a Japanese group in the healthcare active in over 125 countries with a focus on diabetes care, diagnostics, life sciences and healthcare IT. Its subsidiaries include Ascensia, Epredia, PHCbi, Medicom and LSI Medience. The total group employs over 9,800 people and in 2020 the group had a revenue of 306 billion yen (more than €2.2 billion).
Epredia is an American company focused on cancer diagnostics. The company originated from the sale of the anatomical pathology business of Thermo Fisher Scientific to PHC Group in 2019. Epredia is a global provider of comprehensive solutions in the anatomical pathology field, including anatomical pathology instruments, microscope slides and consumables.